BioSpace News Archive

STERIS plc announced financial results for its fiscal 2023 second quarter ended September 30, 2022.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended September 30, 2022.

Akumin Inc., a national partner of choice for U.S. hospitals, health systems and physician groups with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced its financial results for the quarter ended September 30, 2022.

Travere Therapeutics, Inc. announced that Company management will participate in the following upcoming conferences.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data from its completed pharmacokinetic studies of AQST-109 (epinephrine sublingual film) at the American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting.

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2022 financial results and recent portfolio updates.

Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”) today announced that its Chief Executive Officer, President, and Director, Stephen Wilson, PhD, resigned from his positions with Immune on November 3, 2022, citing a lack of Director and Officer insurance.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets.

GreenLight Biosciences Holdings, PBC today reported operational highlights and financial results for the third quarter ended September 30, 2022.